ACURX PHARMACEUTICALS INC (ACXP)
US00510M1045 - Common Stock
ACURX PHARMACEUTICALS INC
NASDAQ:ACXP (1/8/2025, 8:00:00 PM)
After market: 0.805 +0.05 (+7.19%)0.751
-0.06 (-6.88%)
Company Profile
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. The company is headquartered in Staten Island, New York and currently employs 4 full-time employees. The company went IPO on 2021-06-25. The company develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. Phase II clinical data validate the efficacy of its lead antibiotic candidate, as well as pol IIIC as an appropriate bacterial target.
Company Info
ACURX PHARMACEUTICALS INC
259 Liberty Avenue
Staten Island NEW YORK
P: 19175331469
CEO: David P. Luci
Employees: 4
Website: https://www.acurxpharma.com/
ACXP News
19 hours ago - ChartmillStay updated with the stocks that are on the move in today's after-hours session.After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
2 days ago - Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals, Inc. Announces Closing of $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of...
3 days ago - Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals, Inc. Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of...
3 days ago - Acurx Pharmaceuticals, Inc.Acurx Receives Positive Regulatory Guidance from EMA for Ibezapolstat Phase 3 Program for C. Difficile Infection (CDI)Acurx has now received positive written responses from the EMA (European Medicines Agency) under its Scientific Advice Procedure that the clinical,...
a month ago - ACCESSWIREAcurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025a month ago - Acurx Pharmaceuticals, Inc.Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA CommunicationsFollowing the previously announced successful End of Phase 2 Meeting achieving agreement with FDA on non-clinical and clinical Phase 3-readiness, Acurx has now...
ACXP Twits
Here you can normally see the latest stock twits on ACXP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
